Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203957 · ClinicalTrials.gov registry record · Phase 3
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
A Phase 3 study of Parkinson's Disease, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00203957: Completed Phase 3 study of Parkinson's Disease, sponsored by University of Chicago.
NCT00203957 is a Phase 3 study of Parkinson's Disease that has completed, run by University of Chicago. The registered enrollment target is 10 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00203957, a Phase 3 study of Parkinson's Disease, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to confirm the long term tolerability and safety of oral 20 or 40 mg/d doses of Istradefylline.
Conditions Studied
Interventions
- DRUG Istradefylline
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
What the finished NCT00203957 record still lists
NCT00203957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Istradefylline is the first listed.
NCT00203957 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00203957 about?
NCT00203957 is a clinical study titled "Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa". The purpose of this study is to confirm the long term tolerability and safety of oral 20 or 40 mg/d doses of Istradefylline.
What is the current status of trial NCT00203957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2005-03. Estimated completion is 2007-02.
What conditions does trial NCT00203957 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00203957?
The interventions under investigation include: Istradefylline (DRUG).
Who is sponsoring clinical trial NCT00203957?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00203957 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00203957's enrollment target sits among peer trials
10 146th of 158 higher than 8 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ACTIVE NOT RECRUITING · Phase 3
-
Deep Brain Stimulation for Parkinson's Disease Trial
COMPLETED · Phase 3
-
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia